Starling Oncology, Inc.
Close on Oct 19, 2026
- Market cap
- $665.58M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 12, 2026, during market hours (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 6, 2026 | During market hours | $161.30M | $-0.08 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 7, 2026 | During market hours | $147.40M | – | – |
| Q4 FY2025 Ended Dec 31, 2025 | Jan 12, 2026 | Before market open | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 13, 2025 | During market hours | $136.60M | $-0.14 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 13, 2025 | During market hours | $119.80M | $-0.15 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 14, 2025 | During market hours | $104.40M | $-0.21 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 24, 2025 | Before market open | $100.00M | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 13, 2024 | During market hours | $99.90M | $-0.18 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 13, 2024 | During market hours | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 14, 2024 | During market hours | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 27, 2024 | During market hours | – | – | – |
Company guidance
Outlook given with results on Aug 6, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| Adjusted EBITDAnon-GAAP | third quarter of 2026 | $500.00K to $1.50M | New |
| Adjusted EBITDAnon-GAAP | 2026 Guidance - Updated | $2.00M to $7.00M | Narrowed |
| Free Cash Flownon-GAAP | 2026 Guidance - Updated | $5.00M to $15.00M | Maintained |
| Gross Profit | 2026 Guidance - Updated | $105.00M to $110.00M | Raised |
| Medical Loss Rationon-GAAP | the next twelve months | 80% to 90% | – |
| capitated revenue | 2026 | $150.00M | Lowered |
| Revenue | 2026 Guidance - Updated | $650.00M to $670.00M | Raised |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Starling Oncology filed with the SEC
Starling Oncology Reports Second Quarter
Results of operations · EX-99.1 to Form 8-K
The Oncology Institute Rebrands as Starling Oncology
Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
The Oncology Institute Completes Strategic Refinancing with
Material agreement · New financial obligation · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
The Oncology Institute Reports First
Results of operations · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
The Oncology Institute Reports Fourth
Results of operations · EX-99.1 to Form 8-K
The Oncology Institute Appoints Kim Tzoumakas to Board of
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
2025 Guidance and Provides Preliminary 2026 Outlook
Results of operations · EX-99.1 to Form 8-K
Oncology Institute Announces Addition of Board Member Mark Stolper
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
The Oncology Institute Announces Resignation of Board Member
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
The Oncology Institute Reports Third
Results of operations · EX-99.1 to Form 8-K
The Oncology Institute Reports Second
Results of operations · EX-99.1 to Form 8-K
Changes to Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
The Oncology Institute Reports First
Results of operations · EX-99.1 to Form 8-K
CERRITOS, Calif., March 24, 2025 (GLOBE
Material agreement · Unregistered share sale · Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
TOI combines the services of a speciality benefits manager withthe care delivery infrastructure of a provider and pharmacy
Regulation FD disclosure · EX-99.1 to Form 8-K
The Oncology Institute Reports Fourth
Results of operations · EX-99.1 to Form 8-K
The Oncology Institute Announces Amendment
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
The Oncology Institute Reports Third Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
The Oncology Institute Announces CFO Transition
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
The Oncology Institute Reports Second Quarter 2024 Financial Results and Updates Full Year 2024 Guidance
Results of operations · EX-99.1 to Form 8-K
The Oncology Institute Reports First Quarter 2024 Financial Results and Reaffirms Full Year 2024 Guidance
Results of operations · EX-99.1 to Form 8-K
1THE ONCOLOGY INSTITUTE OF HOPE & INNOVATION Investor Presentation April 2024
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
The Oncology Institute Reports Fourth Quarter and Full Year 2023 Financial Results and Guidance for 2024
Results of operations · EX-99.1 to Form 8-K
The Oncology Institute Reports Third Quarter 2023 Financial Results and Reaffirms Full Year 2023 Guidance
Results of operations · EX-99.1 to Form 8-K
The Oncology Institute Regains Compliance with Nasdaq Listing Requirements
Other events · EX-99.1 to Form 8-K
1THE ONCOLOGY INSTITUTE OF HOPE & INNOVATION Investor Presentation AUGUST 2023
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
The Oncology Institute Reports Second Quarter 2023 Financial Results and Reaffirms Full Year 2023 Guidance
Results of operations · EX-99.1 to Form 8-K
THE ONCOLOGY INSTITUTE ANNOUNCES LEADERSHIP TRANSITION
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K/A
EX-99.1 to Form 8-K
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
The Oncology Institute Reports First Quarter 2023 Financial Results and Reaffirms Full Year 2023 Guidance
Results of operations · EX-99.1 to Form 8-K
Capital Deployment Strategy fueled by recent $110 million strategic investment by Deerfield Management 26 | Investor Presentation March 2023 Adjusted EBITDA and Net Income Pro tability projected in 2024 Acquisitions De Novo Growth Operating Losses Working Capital (predominantly funding A/R)
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
CORRECTION -- The Oncology Institute Reports Updated Fourth Quarter and Full Year 2022 Financial Results and Guidance for 2023
Results of operations · EX-99.1 to Form 8-K/A
The Oncology Institute Reports Fourth Quarter and Full Year 2022 Financial Results and Guidance for 2023
Results of operations · EX-99.1 to Form 8-K
Capital Deployment Strategy fueled by recent $110 million strategic investment by Deerfield Management 26 | Investor Presentation November 2022 Adjusted EBITDA and Net Income Pro tability projected in 2024 Acquisitions De Novo Growth Operating Losses Working Capital (predominantly funding A/R)
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
The Oncology Institute Reports Third Quarter 2022 Financial Results and Updates Full Year 2022 Guidance
Results of operations · EX-99.1 to Form 8-K
The Oncology Institute Appoints Two New Board Members
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Capital Deployment Strategy fueled by recent $110 million strategic investment by Deerfield Management 26 Acquisitions De Novo Growth Working Capital (predominantly funding A/R) Operating Losses Adjusted EBITDA and Net Income Profitability projected in 2024
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K